Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice

Journal of Psychopharmacology
Adam L HalberstadtSimon D Brandt

Abstract

In recent years, there has been increasing scientific interest in the effects and pharmacology of serotonergic hallucinogens. While a large amount of experimental work has been conducted to characterize the behavioral response to hallucinogens in rodents, there has been little systematic investigation of mescaline and its analogs. The hallucinogenic potency of mescaline is increased by α-methylation and by homologation of the 4-methoxy group but it not clear whether these structural modifications have similar effects on the activity of mescaline in rodent models. In the present study, the head twitch response (HTR), a 5-HT2A receptor-mediated behavior induced by serotonergic hallucinogens, was used to assess the effects of mescaline and several analogs in C57BL/6J mice. HTR experiments were conducted with mescaline, escaline (4-ethoxy-3,5-dimethoxyphenylethylamine) and proscaline (3,5-dimethoxy-4-propoxyphenylethylamine), their α-methyl homologs TMA (3,4,5-trimethoxyamphetamine), 3C-E (4-ethoxy-3,5-dimethoxyamphetamine) and 3C-P (3,5-dimethoxy-4-propoxyamphetamine), and the 2,4,5-substituted regioisomers TMA-2 (2,4,5-trimethoxyamphetamine), MEM (4-ethoxy-2,5-dimethoxyamphetamine) and MPM (2,5-dimethoxy-4-propoxyamphetamine). TM...Continue Reading

References

Feb 1, 1977·Journal of Medicinal Chemistry·D E Nichols, D C Dyer
May 28, 1975·Psychopharmacologia·M T Silva, H M Calil
Jan 1, 1971·Psychopharmacologia·I D Hirschhorn, J C Winter
Oct 1, 1982·Pharmacology, Biochemistry, and Behavior·R A Glennon, R Young
Sep 1, 1981·Pharmacopsychiatria·E PrzegalínskiA Lewandowska
Sep 25, 1997·Journal of Medicinal Chemistry·A P MonteD E Nichols
Oct 12, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J C Gewirtz, G J Marek
Aug 18, 2001·Pharmacology, Biochemistry, and Behavior·S P VickersG A Kennett
Jun 29, 2005·Psychopharmacology·William E FantegrossiJames H Woods
Nov 10, 2005·Journal of Neurochemistry·Jason C ParrishDavid E Nichols
Feb 8, 2006·Pharmacology, Biochemistry, and Behavior·W E FantegrossiJ H Woods
Oct 2, 2007·Pharmacology, Biochemistry, and Behavior·William E FantegrossiJerrold C Winter
Sep 8, 2010·Archives of General Psychiatry·Charles S GrobGeorge R Greer
Sep 23, 2010·The Journal of Pharmacology and Experimental Therapeutics·W E FantegrossiJ H Woods
Dec 15, 2010·Journal of Psychopharmacology·Adam L HalberstadtMark A Geyer
Jun 21, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Michael KometerFranz X Vollenweider
Jan 9, 2014·ACS Chemical Neuroscience·Martin HansenJesper L Kristensen
Feb 28, 2014·Drug Testing and Analysis·L A King
Sep 13, 2014·Journal of Psychopharmacology·Matthew W JohnsonRoland R Griffiths
Oct 2, 2014·The Journal of Pharmacology and Experimental Therapeutics·Douglas A SmithWilliam E Fantegrossi
Mar 30, 2016·Neuropharmacology·Adam L HalberstadtJared W Young

❮ Previous
Next ❯

Citations

Dec 19, 2019·Frontiers in Pharmacology·Karolina E KolaczynskaMatthias E Liechti
Mar 28, 2020·ACS Chemical Neuroscience·Emil Marcher-RørstedJesper L Kristensen

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear magnetic resonance

Software Mentioned

MPM
MEM
GraphPad
LabChart
Prism

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.